Equities research analysts at StockNews.com started coverage on shares of vTv Therapeutics (NASDAQ:VTVT - Get Free Report) in a research report issued to clients and investors on Saturday. The brokerage set a "sell" rating on the biotechnology company's stock.
Separately, Alliance Global Partners began coverage on vTv Therapeutics in a research note on Monday, December 9th. They issued a "buy" rating and a $35.00 target price for the company.
Check Out Our Latest Stock Analysis on vTv Therapeutics
vTv Therapeutics Price Performance
Shares of NASDAQ:VTVT traded down $2.51 during trading on Friday, hitting $19.20. 3,332 shares of the company were exchanged, compared to its average volume of 9,149. vTv Therapeutics has a 52-week low of $8.10 and a 52-week high of $30.99. The stock has a 50 day moving average of $15.31 and a 200 day moving average of $14.93. The company has a market cap of $61.24 million, a PE ratio of -4.28 and a beta of 0.73.
Institutional Trading of vTv Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC grew its position in shares of vTv Therapeutics by 12.9% during the 4th quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company's stock valued at $158,000 after purchasing an additional 1,327 shares in the last quarter. JPMorgan Chase & Co. bought a new stake in vTv Therapeutics during the fourth quarter valued at $25,000. Finally, FMR LLC purchased a new position in vTv Therapeutics during the third quarter worth about $2,402,000. Institutional investors own 17.51% of the company's stock.
vTv Therapeutics Company Profile
(
Get Free Report)
vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.
See Also
Before you consider vTv Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and vTv Therapeutics wasn't on the list.
While vTv Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
